In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $31. The company’s shares opened today at $33.05.
Rivkind Koffler observed:
“We note that consensus estimates are already toward the top end of the range and investors may have been hoping for a slight guidance raise after mgmt.’s optimistic remarks about rapid uptake of the nerve block utilization amongst anesthesiologists. Pacira remains a challenging stock because of the uncertainty around the takeout thesis in the name, and the overhang from Heron’s pending data releases and launch. We reiterate our Neutral rating.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.3% and a 48.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Eagle Pharmaceuticals, and Revance Therapeutics.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $45.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.48 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 1.19M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. It develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
